<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hypercalcemia of malignancy: Mechanisms</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hypercalcemia of malignancy: Mechanisms</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Hypercalcemia of malignancy: Mechanisms</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mara J Horwitz, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Clifford J Rosen, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jean E Mulder, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 26, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hypercalcemia is relatively common in patients with cancer, occurring in approximately 20 to 30 percent of cases [<a href="#rid1">1</a>]. It is the most common cause of hypercalcemia in the inpatient setting. It occurs in patients with both solid tumors and hematologic malignancies. The most common cancers associated with hypercalcemia in the United States are breast, renal, lung, and squamous cell cancers and multiple myeloma [<a href="#rid2">2</a>]. Malignancy is usually evident clinically by the time it causes hypercalcemia, and patients with hypercalcemia of malignancy often have a poor prognosis. The mechanisms of hypercalcemia will be reviewed here. The clinical manifestations, diagnosis, and treatment of hypercalcemia are reviewed in detail separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/832.html" rel="external">"Clinical manifestations of hypercalcemia"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/836.html" rel="external">"Diagnostic approach to hypercalcemia"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/850.html" rel="external">"Treatment of hypercalcemia"</a>.)</p><p></p><p class="headingAnchor" id="H2021818767"><span class="h1">MECHANISMS OF HYPERCALCEMIA</span><span class="headingEndMark"> — </span>There are three major mechanisms by which hypercalcemia of malignancy can occur  (<a class="graphic graphic_table graphicRef74189" href="/d/graphic/74189.html" rel="external">table 1</a>) [<a href="#rid3">3-5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Tumor secretion of parathyroid hormone-related protein (PTHrP)</p><p class="bulletIndent1"><span class="glyph">●</span>Osteolytic metastases with local release of cytokines (including osteoclast activating factors)</p><p class="bulletIndent1"><span class="glyph">●</span>Tumor production of 1,25-dihydroxyvitamin D (calcitriol)</p><p></p><p>Ectopic tumoral secretion of parathyroid hormone (PTH) can also cause hypercalcemia, but it is rare.</p><p class="headingAnchor" id="H1048261776"><span class="h2">PTH-related protein</span><span class="headingEndMark"> — </span>The most common cause of hypercalcemia in patients with nonmetastatic solid tumors and in some patients with non-Hodgkin lymphoma is secretion of parathyroid hormone (PTH)-related protein (PTHrP); this condition, also called humoral hypercalcemia of malignancy (HHM), accounts for up to 80 percent of patients with hypercalcemia of malignancy [<a href="#rid6">6-9</a>]. Patients with HHM most often have squamous cell carcinomas (lung, head, and neck), renal, bladder, breast, or ovarian carcinomas  (<a class="graphic graphic_table graphicRef74189" href="/d/graphic/74189.html" rel="external">table 1</a>). They typically have advanced disease and a poor prognosis [<a href="#rid10">10-12</a>].</p><p>PTHrP is a normal gene product expressed in a wide variety of neuroendocrine, epithelial, and mesoderm-derived tissues. Thus, in addition to patients with solid tumors, those with non-Hodgkin lymphoma [<a href="#rid6">6,7,13</a>], chronic myeloid leukemia (blast phase) [<a href="#rid14">14</a>], and adult T cell leukemia lymphoma may have PTHrP-induced hypercalcemia [<a href="#rid7">7,15,16</a>]. Tumor necrosis factor-beta also may contribute in some patients with adult T cell leukemia lymphoma [<a href="#rid17">17</a>]. (See  <a class="medical medical_review" href="/d/html/4697.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of adult T cell leukemia-lymphoma", section on 'Pathogenesis'</a>.)</p><p>Purification of PTHrP has revealed some homology with PTH, particularly at the amino-terminal end, at which the first 13 amino acids are almost identical [<a href="#rid18">18</a>]. As a result of this close homology with PTH, PTHrP binds to the same PTH-1 receptor as does PTH and thus activates similar postreceptor pathways. This accounts for the ability of PTHrP to simulate some of the actions of PTH, including increases in bone resorption and distal tubular calcium reabsorption and inhibition of proximal tubular phosphate transport [<a href="#rid8">8,19-21</a>].</p><p>Structural divergence after the first 13 amino acids of the molecule accounts for its immunologic distinctiveness from PTH. PTHrP is less likely than PTH to stimulate 1,25-dihydroxyvitamin D production [<a href="#rid8">8,22-25</a>], although 1,25-dihydroxyvitamin D measurement in patients with PTHrP-mediated hypercalcemia may be variable [<a href="#rid5">5</a>]. In patients with HHM, there is an uncoupling of bone resorption and formation, which results in a large flux of calcium from bone into the circulation. In combination with the reduced ability of the kidney to clear calcium, this results in the striking hypercalcemia that occurs in HHM. Thus, hypercalcemia in HHM is predominantly due to the combined effects of PTHrP on kidney and bone [<a href="#rid8">8,19,26</a>].</p><p>Typical laboratory findings in patients with HHM include the following [<a href="#rid1">1,8,27</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Elevated serum PTHrP</p><p class="bulletIndent1"><span class="glyph">●</span>Very low or suppressed serum intact PTH (secretion of endogenous PTH is suppressed by PTHrP-mediated hypercalcemia)</p><p class="bulletIndent1"><span class="glyph">●</span>Variable serum 1,25-dihydroxyvitamin D</p><p></p><p>Serum PTHrP levels in patients with tumor-induced hypercalcemia can provide information regarding prognosis:</p><p class="bulletIndent1"><span class="glyph">●</span>It is a useful tumor marker for assessing the response to treatment of the tumor.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>It may predict the response to antiresorptive agents. Serum PTHrP concentrations above 12 pmol/L are frequently associated with both a smaller reduction in hypercalcemia and with recurrence of hypercalcemia within 14 days of therapy [<a href="#rid10">10,28,29</a>]. While the prognosis of cancer-associated hypercalcemia is generally poor, those who become normocalcemic with bisphosphonate therapy have a significantly better, although still short, survival (53 versus 19 days in one study) [<a href="#rid29">29</a>]. (See  <a class="medical medical_review" href="/d/html/850.html" rel="external">"Treatment of hypercalcemia", section on 'Choice of antiresorptive agent: Bisphosphonates'</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h2">Osteolytic metastases</span><span class="headingEndMark"> — </span>Osteolytic metastases account for approximately 20 percent of cases of hypercalcemia of malignancy [<a href="#rid9">9</a>]. Induction of local osteolysis by tumor cells is common with some solid tumors that are metastatic to bone and with multiple myeloma, but it is less common with lymphoma and leukemia  (<a class="graphic graphic_table graphicRef74189" href="/d/graphic/74189.html" rel="external">table 1</a>) [<a href="#rid4">4,5</a>]. The solid tumor that most often produces hypercalcemia by this mechanism is breast cancer.</p><p>The bone destruction observed in osteolytic metastases is primarily mediated by osteoclasts and is not a direct effect of tumor cells [<a href="#rid30">30</a>]. Instead, tumors produce many factors that stimulate osteoclast production and action locally, resulting in increased skeletal resorption and hypercalcemia. (See  <a class="medical medical_review" href="/d/html/2828.html" rel="external">"Mechanisms of bone metastases", section on 'Osteolytic versus osteoblastic bone metastases'</a>.)</p><p>Typical findings in patients with osteolytic metastases include:</p><p class="bulletIndent1"><span class="glyph">●</span>Low or suppressed serum intact PTH</p><p class="bulletIndent1"><span class="glyph">●</span>Low or low-normal serum 1,25-dihydroxyvitamin D</p><p class="bulletIndent1"><span class="glyph">●</span>Low or low-normal serum PTHrP (although tumor metastases in bone may secrete PTHrP locally, it is not usually measurable in a serum assay)</p><p class="bulletIndent1"><span class="glyph">●</span>Extensive skeletal metastases or marrow infiltration</p><p></p><p class="headingAnchor" id="H3"><span class="h3">Breast cancer</span><span class="headingEndMark"> — </span>Breast cancer cells in bone express PTHrP more frequently than those in soft tissue sites or in the primary tumor. PTHrP produced by metastatic tumor cells in the bone microenvironment acts as a local (rather than systemic) factor to cause osteolysis [<a href="#rid27">27</a>]. This occurs in the absence of high serum PTHrP concentrations. However, in other patients with breast cancer, bone metastases, and hypercalcemia, serum PTHrP is elevated, suggesting a systemic effect as well [<a href="#rid31">31</a>]. (See <a class="local">'PTH-related protein'</a> above.)</p><p>Locally produced PTHrP increases expression of receptor activator of nuclear factor kappa-B (RANK) ligand (RANKL) in bone. RANKL contributes to the development of hypercalcemia by binding to RANK on the surface of osteoclast precursors. The RANKL/RANK interaction results in activation, migration, differentiation, and fusion of hematopoietic cells of the osteoclast lineage to begin the process of resorption. In addition, cytokines such as interleukin (IL)-6, IL-8, IL-1, and vascular endothelial growth factor (VEGF) are secreted by breast cancer cells and may contribute to the effects of PTHrP on bone resorption. (See  <a class="medical medical_review" href="/d/html/2828.html" rel="external">"Mechanisms of bone metastases", section on 'Osteolytic versus osteoblastic bone metastases'</a>.)</p><p>Among patients with breast cancer and extensive skeletal metastases, the administration of an antiestrogen (such as <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a>) can lead to hypercalcemia [<a href="#rid32">32,33</a>]. The presumed mechanism is release of bone resorbing factors from the tumor cells [<a href="#rid34">34</a>]. In addition, there have been case reports of flare hypercalcemia<strong> </strong>with aromatase inhibitors [<a href="#rid35">35,36</a>].</p><p class="headingAnchor" id="H4"><span class="h3">Multiple myeloma</span><span class="headingEndMark"> — </span>Hypercalcemia in multiple myeloma and in some cases of lymphoma where there is bone marrow infiltration by tumor has been ascribed to the release of osteoclast-activating factors by the tumor cells [<a href="#rid37">37,38</a>]. Osteoclast-induced bone resorption may occur in discrete focal areas (lytic lesions) or throughout the skeleton. The high rate of bone resorption is associated with an absence of osteoblast-mediated bone formation, resulting in diffuse bone loss. The uncoupling of bone resorption and formation results from paracrine factors, which enhance osteoclast formation and activity and inhibit the capacity for marrow stromal cells to differentiate into osteoblasts [<a href="#rid37">37,38</a>]. In multiple myeloma, various studies have implicated cytokine release, pro-osteoclastogenic factors, an increase in RANKL production by osteocytes and inhibition of osteoblasts as factors contributing to the development of lytic bone disease and hypercalcemia [<a href="#rid39">39</a>]. (See  <a class="medical medical_review" href="/d/html/2828.html" rel="external">"Mechanisms of bone metastases", section on 'Osteolytic versus osteoblastic bone metastases'</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">1,25-dihydroxyvitamin D</span><span class="headingEndMark"> — </span>Increased production of 1,25-dihydroxyvitamin D (calcitriol) is the cause of almost all cases of hypercalcemia in Hodgkin lymphoma and approximately one-third of cases in non-Hodgkin lymphoma  (<a class="graphic graphic_table graphicRef74189" href="/d/graphic/74189.html" rel="external">table 1</a>) [<a href="#rid13">13,38,40</a>]. An occasional patient with Hodgkin lymphoma, however, has hypercalcemia due to PTHrP, as do some with non-Hodgkin lymphoma, as stated above [<a href="#rid6">6,13,41</a>]. Additionally, there are rare cases of calcitriol mediated hypercalcemia in patients with solid tumors [<a href="#rid42">42</a>]. 1,25-dihydroxyvitamin D-induced hypercalcemia has also been described in patients with ovarian dysgerminoma [<a href="#rid43">43</a>] and lymphomatoid granulomatosis/angiocentric lymphoma [<a href="#rid44">44</a>]; the latter finding is consistent with the frequent association of hypercalcemia with chronic granulomatous diseases, such as sarcoidosis and tuberculosis. (See  <a class="medical medical_review" href="/d/html/841.html" rel="external">"Hypercalcemia in granulomatous diseases"</a>.)</p><p>In normal individuals, the conversion of 25-hydroxyvitamin D (calcidiol) to 1,25-dihydroxyvitamin D (calcitriol, the most active metabolite of vitamin D) occurs via a 1-hydroxylase in the kidney that is under the physiologic control of PTH and inhibited by high serum phosphate via fibroblast growth factor 23 (FGF-23) (see  <a class="medical medical_review" href="/d/html/2033.html" rel="external">"Overview of vitamin D", section on 'Metabolism'</a>). Hypercalcemia should suppress the release of PTH and therefore the production of 1,25-dihydroxyvitamin D. The lack of suppression of 1,25-dihydroxyvitamin D production in lymphoma is due to PTH-independent extrarenal production of 1,25-dihydroxyvitamin D from 25-hydroxyvitamin D by malignant lymphocytes, macrophages, or both.</p><p>Increased intestinal calcium absorption induced by high serum 1,25-dihydroxyvitamin D concentrations is the primary abnormality, although a 1,25-dihydroxyvitamin D-induced increase in bone resorption may play a contributory role. Patients with increased production of 1,25-dihydroxyvitamin D typically have low or suppressed serum intact PTH and elevated 1,25-dihydroxyvitamin D. In case reports, some patients have elevations of both 1,25-dihydroxyvitamin D and PTHrP [<a href="#rid45">45</a>]. Hypercalcemia induced by 1,25-dihydroxyvitamin D (but not PTHRP) usually responds to glucocorticoid therapy. (See  <a class="medical medical_review" href="/d/html/850.html" rel="external">"Treatment of hypercalcemia", section on 'Disease-specific approach'</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Ectopic PTH secretion</span><span class="headingEndMark"> — </span>A few patients with ectopic secretion of parathyroid hormone (PTH) have been described; among the tumors were an ovarian carcinoma, small cell and squamous cell lung carcinomas, a primitive neuroectodermal tumor, thyroid papillary carcinoma, metastatic rhabdomyosarcoma, pancreatic malignancy, and gastric carcinoma  (<a class="graphic graphic_table graphicRef74189" href="/d/graphic/74189.html" rel="external">table 1</a>) [<a href="#rid46">46-54</a>]. In these case reports, serum intact PTH was elevated, and some patients were diagnosed after neck exploration failed to identify a parathyroid adenoma.</p><p class="headingAnchor" id="H9"><span class="h1">COEXISTING PRIMARY HYPERPARATHYROIDISM</span><span class="headingEndMark"> — </span>There is a higher incidence of cancer in patients with primary hyperparathyroidism and of primary hyperparathyroidism in patients with cancer [<a href="#rid55">55,56</a>]. Thus, serum parathyroid hormone (PTH) should be measured in hypercalcemic patients with cancer [<a href="#rid57">57</a>]. If serum parathyroid hormone-related protein (PTHrP) and PTH concentrations are both high, then coexisting primary hyperparathyroidism is probably present as well. However, there have been rare reports of tumors simultaneously secreting both PTH and PTHrP [<a href="#rid58">58</a>]. </p><p>Mild hypercalcemia due to primary hyperparathyroidism often precedes the acute and more severe hypercalcemia that is seen with hypercalcemia of malignancy. If serum PTH is elevated and PTHrP is not elevated, then primary hyperparathyroidism is probably the sole cause for the hypercalcemia [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/d/html/2029.html" rel="external">"Primary hyperparathyroidism: Diagnosis, differential diagnosis, and evaluation"</a>.)</p><p class="headingAnchor" id="H4288754659"><span class="h1">DETERMINING THE MECHANISM</span><span class="headingEndMark"> — </span>Most patients with hypercalcemia of malignancy have clinical evidence of malignancy at the time of hypercalcemia diagnosis. Humoral hypercalcemia is likely the cause of hypercalcemia in any patient with a solid tumor in the absence of bony metastases. Local release of cytokines from osteolytic metastases is the likely cause of hypercalcemia in patients with extensive skeletal metastases or marrow infiltration. Hypercalcemia induced by 1,25-dihydroxyvitamin D should be suspected in patients with lymphoma.</p><p>Hypercalcemia of malignancy should also be suspected in patients with otherwise unexplained hypercalcemia and a low serum parathyroid hormone (PTH) concentration. (See  <a class="medical medical_review" href="/d/html/839.html" rel="external">"Etiology of hypercalcemia"</a>.)</p><p>The approach to determining the mechanism of hypercalcemia is reviewed briefly below and in more detail separately  (<a class="graphic graphic_algorithm graphicRef51698" href="/d/graphic/51698.html" rel="external">algorithm 1</a>) (see  <a class="medical medical_review" href="/d/html/836.html" rel="external">"Diagnostic approach to hypercalcemia"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Once hypercalcemia is confirmed, we measure concomitantly serum PTH and calcium. An elevated or mid- to upper-normal value with persistent hypercalcemia generally indicates primary hyperparathyroidism.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the presence of low-normal or low serum PTH concentrations (eg, &lt;20 pg/mL), PTH-related protein (PTHrP) and vitamin D metabolites should be measured to assess for hypercalcemia of malignancy and vitamin D intoxication.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Elevated PTHrP is consistent with humoral hypercalcemia of malignancy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Increased levels of 1,25-dihydroxyvitamin D may be induced by direct intake of this metabolite, extrarenal production in granulomatous diseases or lymphoma, or increased renal production that can be induced by primary hyperparathyroidism or ectopic PTH secretion but not by PTHrP.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Markedly elevated 25-hydroxyvitamin D is consistent with vitamin D intoxication. Although the serum concentration of 25(OH)D at which hypercalcemia typically occurs is undefined, many experts define vitamin D intoxication as a value &gt;150 ng/mL (374 nmol/L) [<a href="#rid59">59</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If PTHrP and vitamin D metabolites are not elevated, another source for the hypercalcemia must be considered. Additional laboratory data (including serum and urine protein electrophoresis and serum free light chain assay for possible multiple myeloma, thyroid-stimulating hormone [TSH], and vitamin A) will often lead to the correct diagnosis. Some patients may require imaging (eg, skeletal radiographs) for diagnosis of osteolytic metastases if the diagnosis is not clear from history. (See  <a class="medical medical_review" href="/d/html/836.html" rel="external">"Diagnostic approach to hypercalcemia", section on 'Other tests'</a>.)</p><p></p><p class="headingAnchor" id="H3828770985"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>The treatment of hypercalcemia is reviewed separately. (See  <a class="medical medical_review" href="/d/html/850.html" rel="external">"Treatment of hypercalcemia", section on 'Preferred approach'</a>.)</p><p class="headingAnchor" id="H10"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cancers associated with hypercalcemia</strong> – Hypercalcemia is relatively common in patients with cancer, occurring in approximately 20 to 30 percent of cases, and it is associated with a poor prognosis. The most common tumors that cause hypercalcemia are breast cancer, renal cancer, lung cancer, multiple myeloma, lymphoma, and squamous cell cancers  (<a class="graphic graphic_table graphicRef74189" href="/d/graphic/74189.html" rel="external">table 1</a>). (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathophysiology of hypercalcemia of malignancy</strong> – There are three major mechanisms by which hypercalcemia of malignancy can occur:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Tumor secretion of parathyroid hormone-related protein (PTHrP)</strong> – Hypercalcemia is due to both increased bone resorption and increased distal renal tubular calcium reabsorption. (See <a class="local">'PTH-related protein'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Osteolytic metastases with local release of cytokines</strong> – Hypercalcemia is primarily due to increased bone resorption and release of calcium from bone. (See <a class="local">'Osteolytic metastases'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Tumor production of 1,25-dihydroxyvitamin D</strong> – Hypercalcemia is the result of a combination of increased intestinal calcium absorption and bone resorption. (See <a class="local">'1,25-dihydroxyvitamin D'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Determining the etiology of hypercalcemia</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Measure concomitantly repeat calcium and parathyroid hormone (PTH)</strong> – An elevated or mid- to upper-normal value with persistent hypercalcemia generally indicates primary hyperparathyroidism  (<a class="graphic graphic_algorithm graphicRef51698" href="/d/graphic/51698.html" rel="external">algorithm 1</a>). (See <a class="local">'Determining the mechanism'</a> above and  <a class="medical medical_review" href="/d/html/836.html" rel="external">"Diagnostic approach to hypercalcemia"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Measure PTHrP and vitamin D metabolites</strong> – In the presence of low-normal or low serum PTH concentrations (eg, &lt;20 pg/mL), PTHrP and vitamin D metabolites should be measured to assess for hypercalcemia of malignancy and vitamin D intoxication. (See <a class="local">'Determining the mechanism'</a> above and  <a class="medical medical_review" href="/d/html/836.html" rel="external">"Diagnostic approach to hypercalcemia"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Additional testing</strong> – If PTHrP and vitamin D metabolites are not elevated, another source for the hypercalcemia must be considered. Additional laboratory data (including serum and urine protein electrophoresis and serum free light chain assay for possible multiple myeloma, thyroid-stimulating hormone [TSH], and vitamin A) will often lead to the correct diagnosis. (See <a class="local">'Determining the mechanism'</a> above and  <a class="medical medical_review" href="/d/html/836.html" rel="external">"Diagnostic approach to hypercalcemia", section on 'Other tests'</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Stewart AF. Clinical practice. Hypercalcemia associated with cancer. N Engl J Med 2005; 352:373.</a></li><li><a class="nounderline abstract_t">Gastanaga VM, Schwartzberg LS, Jain RK, et al. Prevalence of hypercalcemia among cancer patients in the United States. Cancer Med 2016; 5:2091.</a></li><li><a class="nounderline abstract_t">Clines GA, Guise TA. Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone. Endocr Relat Cancer 2005; 12:549.</a></li><li><a class="nounderline abstract_t">Mirrakhimov AE. Hypercalcemia of Malignancy: An Update on Pathogenesis and Management. N Am J Med Sci 2015; 7:483.</a></li><li><a class="nounderline abstract_t">Guise TA, Wysolmerski JJ. Cancer-Associated Hypercalcemia. N Engl J Med 2022; 386:1443.</a></li><li><a class="nounderline abstract_t">Ratcliffe WA, Hutchesson AC, Bundred NJ, Ratcliffe JG. Role of assays for parathyroid-hormone-related protein in investigation of hypercalcaemia. Lancet 1992; 339:164.</a></li><li><a class="nounderline abstract_t">Ikeda K, Ohno H, Hane M, et al. Development of a sensitive two-site immunoradiometric assay for parathyroid hormone-related peptide: evidence for elevated levels in plasma from patients with adult T-cell leukemia/lymphoma and B-cell lymphoma. J Clin Endocrinol Metab 1994; 79:1322.</a></li><li><a class="nounderline abstract_t">Horwitz MJ, Tedesco MB, Sereika SM, et al. Direct comparison of sustained infusion of human parathyroid hormone-related protein-(1-36) [hPTHrP-(1-36)] versus hPTH-(1-34) on serum calcium, plasma 1,25-dihydroxyvitamin D concentrations, and fractional calcium excretion in healthy human volunteers. J Clin Endocrinol Metab 2003; 88:1603.</a></li><li class="breakAll">Horwitz MJ. Non-parathyroid hypercalcemia. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 9th ed, Bilezikian JP (Ed), Wiley-Blackwell, Hoboken, NJ 2018. p.639.</li><li><a class="nounderline abstract_t">Wimalawansa SJ. Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate. Cancer 1994; 73:2223.</a></li><li><a class="nounderline abstract_t">Pecherstorfer M, Schilling T, Blind E, et al. Parathyroid hormone-related protein and life expectancy in hypercalcemic cancer patients. J Clin Endocrinol Metab 1994; 78:1268.</a></li><li><a class="nounderline abstract_t">Bhandari S, Kumar R, Tripathi P, et al. Outcomes of hypercalcemia of malignancy in patients with solid cancer: a national inpatient analysis. Med Oncol 2019; 36:90.</a></li><li><a class="nounderline abstract_t">Roodman GD. Mechanisms of bone lesions in multiple myeloma and lymphoma. Cancer 1997; 80:1557.</a></li><li><a class="nounderline abstract_t">Seymour JF, Grill V, Martin TJ, et al. Hypercalcemia in the blastic phase of chronic myeloid leukemia associated with elevated parathyroid hormone-related protein. Leukemia 1993; 7:1672.</a></li><li><a class="nounderline abstract_t">Nakamura Y, Bando H, Shintani Y, et al. Serum parathyroid hormone-related protein concentrations in patients with hematologic malignancies or solid tumors. Acta Endocrinol (Copenh) 1992; 127:324.</a></li><li><a class="nounderline abstract_t">Inoue D, Matsumoto T, Ogata E, Ikeda K. 22-Oxacalcitriol, a noncalcemic analogue of calcitriol, suppresses both cell proliferation and parathyroid hormone-related peptide gene expression in human T cell lymphotrophic virus, type I-infected T cells. J Biol Chem 1993; 268:16730.</a></li><li><a class="nounderline abstract_t">Ishibashi K, Ishitsuka K, Chuman Y, et al. Tumor necrosis factor-beta in the serum of adult T-cell leukemia with hypercalcemia. Blood 1991; 77:2451.</a></li><li><a class="nounderline abstract_t">Burtis WJ, Brady TG, Orloff JJ, et al. Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer. N Engl J Med 1990; 322:1106.</a></li><li><a class="nounderline abstract_t">Rizzoli R, Ferrari SL, Pizurki L, et al. Actions of parathyroid hormone and parathyroid hormone-related protein. J Endocrinol Invest 1992; 15:51.</a></li><li><a class="nounderline abstract_t">Fraher LJ, Hodsman AB, Jonas K, et al. A comparison of the in vivo biochemical responses to exogenous parathyroid hormone-(1-34) [PTH-(1-34)] and PTH-related peptide-(1-34) in man. J Clin Endocrinol Metab 1992; 75:417.</a></li><li><a class="nounderline abstract_t">Esbrit P, Egido J. The emerging role of parathyroid hormone-related protein as a renal regulating factor. Nephrol Dial Transplant 2000; 15:1109.</a></li><li><a class="nounderline abstract_t">Schilling T, Pecherstorfer M, Blind E, et al. Parathyroid hormone-related protein (PTHrP) does not regulate 1,25-dihydroxyvitamin D serum levels in hypercalcemia of malignancy. J Clin Endocrinol Metab 1993; 76:801.</a></li><li><a class="nounderline abstract_t">Schweitzer DH, Hamdy NA, Frölich M, et al. Malignancy-associated hypercalcaemia: resolution of controversies over vitamin D metabolism by a pathophysiological approach to the syndrome. Clin Endocrinol (Oxf) 1994; 41:251.</a></li><li><a class="nounderline abstract_t">Nakayama K, Fukumoto S, Takeda S, et al. Differences in bone and vitamin D metabolism between primary hyperparathyroidism and malignancy-associated hypercalcemia. J Clin Endocrinol Metab 1996; 81:607.</a></li><li><a class="nounderline abstract_t">Horwitz MJ, Tedesco MB, Sereika SM, et al. Continuous PTH and PTHrP infusion causes suppression of bone formation and discordant effects on 1,25(OH)2 vitamin D. J Bone Miner Res 2005; 20:1792.</a></li><li><a class="nounderline abstract_t">Syed MA, Horwitz MJ, Tedesco MB, et al. Parathyroid hormone-related protein-(1--36) stimulates renal tubular calcium reabsorption in normal human volunteers: implications for the pathogenesis of humoral hypercalcemia of malignancy. J Clin Endocrinol Metab 2001; 86:1525.</a></li><li><a class="nounderline abstract_t">Mundy GR, Edwards JR. PTH-related peptide (PTHrP) in hypercalcemia. J Am Soc Nephrol 2008; 19:672.</a></li><li><a class="nounderline abstract_t">Gurney H, Grill V, Martin TJ. Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia. Lancet 1993; 341:1611.</a></li><li><a class="nounderline abstract_t">Ling PJ, A'Hern RP, Hardy JR. Analysis of survival following treatment of tumour-induced hypercalcaemia with intravenous pamidronate (APD). Br J Cancer 1995; 72:206.</a></li><li><a class="nounderline abstract_t">Quinn JM, Matsumura Y, Tarin D, et al. Cellular and hormonal mechanisms associated with malignant bone resorption. Lab Invest 1994; 71:465.</a></li><li><a class="nounderline abstract_t">Grill V, Ho P, Body JJ, et al. Parathyroid hormone-related protein: elevated levels in both humoral hypercalcemia of malignancy and hypercalcemia complicating metastatic breast cancer. J Clin Endocrinol Metab 1991; 73:1309.</a></li><li><a class="nounderline abstract_t">Legha SS, Powell K, Buzdar AU, Blumenschein GR. Tamoxifen-induced hypercalcemia in breast cancer. Cancer 1981; 47:2803.</a></li><li><a class="nounderline abstract_t">Arumugam GP, Sundravel S, Shanthi P, Sachdanandam P. Tamoxifen flare hypercalcemia: an additional support for gallium nitrate usage. J Bone Miner Metab 2006; 24:243.</a></li><li><a class="nounderline abstract_t">Valentin-Opran A, Eilon G, Saez S, Mundy GR. Estrogens and antiestrogens stimulate release of bone resorbing activity by cultured human breast cancer cells. J Clin Invest 1985; 75:726.</a></li><li><a class="nounderline abstract_t">Kuroi K, Yamashita T, Aruga T, et al. Flare hypercalcemia after letrozole in a patient with liver metastasis from breast cancer: a case report. J Med Case Rep 2011; 5:495.</a></li><li><a class="nounderline abstract_t">Järhult J. Anastrozole can cause severe hypercalcaemia mimicking primary hyperparathyroidism. Breast Cancer 2014; 21:379.</a></li><li><a class="nounderline abstract_t">Terpos E, Christoulas D, Gavriatopoulou M. Biology and treatment of myeloma related bone disease. Metabolism 2018; 80:80.</a></li><li class="breakAll">Edwards CM, Silberman R. Myeloma bone disease and other hematological malignancies. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 9th ed, Bilezikian JP (Ed), Wiley-Blackwell, Hoboken, NJ 2018. p.760.</li><li><a class="nounderline abstract_t">Terpos E, Ntanasis-Stathopoulos I, Gavriatopoulou M, Dimopoulos MA. Pathogenesis of bone disease in multiple myeloma: from bench to bedside. Blood Cancer J 2018; 8:7.</a></li><li><a class="nounderline abstract_t">Seymour JF, Gagel RF. Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin's disease and non-Hodgkin's lymphomas. Blood 1993; 82:1383.</a></li><li><a class="nounderline abstract_t">Henderson JE, Shustik C, Kremer R, et al. Circulating concentrations of parathyroid hormone-like peptide in malignancy and in hyperparathyroidism. J Bone Miner Res 1990; 5:105.</a></li><li><a class="nounderline abstract_t">Chukir T, Liu Y, Hoffman K, et al. Calcitriol Elevation Is Associated with a Higher Risk of Refractory Hypercalcemia of Malignancy in Solid Tumors. J Clin Endocrinol Metab 2020; 105.</a></li><li><a class="nounderline abstract_t">Hibi M, Hara F, Tomishige H, et al. 1,25-dihydroxyvitamin D-mediated hypercalcemia in ovarian dysgerminoma. Pediatr Hematol Oncol 2008; 25:73.</a></li><li><a class="nounderline abstract_t">Scheinman SJ, Kelberman MW, Tatum AH, Zamkoff KW. Hypercalcemia with excess serum 1,25 dihydroxyvitamin D in lymphomatoid granulomatosis/angiocentric lymphoma. Am J Med Sci 1991; 301:178.</a></li><li><a class="nounderline abstract_t">Shivnani SB, Shelton JM, Richardson JA, Maalouf NM. Hypercalcemia of malignancy with simultaneous elevation in serum parathyroid hormone--related peptide and 1,25-dihydroxyvitamin D in a patient with metastatic renal cell carcinoma. Endocr Pract 2009; 15:234.</a></li><li><a class="nounderline abstract_t">Yoshimoto K, Yamasaki R, Sakai H, et al. Ectopic production of parathyroid hormone by small cell lung cancer in a patient with hypercalcemia. J Clin Endocrinol Metab 1989; 68:976.</a></li><li><a class="nounderline abstract_t">Nussbaum SR, Gaz RD, Arnold A. Hypercalcemia and ectopic secretion of parathyroid hormone by an ovarian carcinoma with rearrangement of the gene for parathyroid hormone. N Engl J Med 1990; 323:1324.</a></li><li><a class="nounderline abstract_t">Strewler GJ, Budayr AA, Clark OH, Nissenson RA. Production of parathyroid hormone by a malignant nonparathyroid tumor in a hypercalcemic patient. J Clin Endocrinol Metab 1993; 76:1373.</a></li><li><a class="nounderline abstract_t">Nielsen PK, Rasmussen AK, Feldt-Rasmussen U, et al. Ectopic production of intact parathyroid hormone by a squamous cell lung carcinoma in vivo and in vitro. J Clin Endocrinol Metab 1996; 81:3793.</a></li><li><a class="nounderline abstract_t">Wong K, Tsuda S, Mukai R, et al. Parathyroid hormone expression in a patient with metastatic nasopharyngeal rhabdomyosarcoma and hypercalcemia. Endocrine 2005; 27:83.</a></li><li><a class="nounderline abstract_t">VanHouten JN, Yu N, Rimm D, et al. Hypercalcemia of malignancy due to ectopic transactivation of the parathyroid hormone gene. J Clin Endocrinol Metab 2006; 91:580.</a></li><li><a class="nounderline abstract_t">Vacher-Coponat H, Opris A, Denizot A, et al. Hypercalcaemia induced by excessive parathyroid hormone secretion in a patient with a neuroendocrine tumour. Nephrol Dial Transplant 2005; 20:2832.</a></li><li><a class="nounderline abstract_t">Kandil E, Noureldine S, Khalek MA, et al. Ectopic secretion of parathyroid hormone in a neuroendocrine tumor: a case report and review of the literature. Int J Clin Exp Med 2011; 4:234.</a></li><li><a class="nounderline abstract_t">Nakajima K, Tamai M, Okaniwa S, et al. Humoral hypercalcemia associated with gastric carcinoma secreting parathyroid hormone: a case report and review of the literature. Endocr J 2013; 60:557.</a></li><li><a class="nounderline abstract_t">Hutchesson AC, Bundred NJ, Ratcliffe WA. Survival in hypercalcaemic patients with cancer and co-existing primary hyperparathyroidism. Postgrad Med J 1995; 71:28.</a></li><li><a class="nounderline abstract_t">Strodel WE, Thompson NW, Eckhauser FE, Knol JA. Malignancy and concomitant primary hyperparathyroidism. J Surg Oncol 1988; 37:10.</a></li><li><a class="nounderline abstract_t">Casez J, Pfammatter R, Nguyen Q, et al. Diagnostic approach to hypercalcemia: relevance of parathyroid hormone and parathyroid hormone-related protein measurements. Eur J Intern Med 2001; 12:344.</a></li><li><a class="nounderline abstract_t">Motlaghzadeh Y, Bilezikian JP, Sellmeyer DE. Rare Causes of Hypercalcemia: 2021 Update. J Clin Endocrinol Metab 2021; 106:3113.</a></li><li><a class="nounderline abstract_t">Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357:266.</a></li></ol></div><div id="topicVersionRevision">Topic 842 Version 16.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15673803" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Clinical practice. Hypercalcemia associated with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27263488" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Prevalence of hypercalcemia among cancer patients in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16172192" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26713296" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Hypercalcemia of Malignancy: An Update on Pathogenesis and Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35417639" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Cancer-Associated Hypercalcemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1346019" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Role of assays for parathyroid-hormone-related protein in investigation of hypercalcaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7962324" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Development of a sensitive two-site immunoradiometric assay for parathyroid hormone-related peptide: evidence for elevated levels in plasma from patients with adult T-cell leukemia/lymphoma and B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12679445" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Direct comparison of sustained infusion of human parathyroid hormone-related protein-(1-36) [hPTHrP-(1-36)] versus hPTH-(1-34) on serum calcium, plasma 1,25-dihydroxyvitamin D concentrations, and fractional calcium excretion in healthy human volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12679445" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Direct comparison of sustained infusion of human parathyroid hormone-related protein-(1-36) [hPTHrP-(1-36)] versus hPTH-(1-34) on serum calcium, plasma 1,25-dihydroxyvitamin D concentrations, and fractional calcium excretion in healthy human volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8156530" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8175989" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Parathyroid hormone-related protein and life expectancy in hypercalcemic cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31529163" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Outcomes of hypercalcemia of malignancy in patients with solid cancer: a national inpatient analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9362422" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Mechanisms of bone lesions in multiple myeloma and lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8412332" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Hypercalcemia in the blastic phase of chronic myeloid leukemia associated with elevated parathyroid hormone-related protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1280391" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Serum parathyroid hormone-related protein concentrations in patients with hematologic malignancies or solid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8393873" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : 22-Oxacalcitriol, a noncalcemic analogue of calcitriol, suppresses both cell proliferation and parathyroid hormone-related peptide gene expression in human T cell lymphotrophic virus, type I-infected T cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2039827" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Tumor necrosis factor-beta in the serum of adult T-cell leukemia with hypercalcemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2320080" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1338636" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Actions of parathyroid hormone and parathyroid hormone-related protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1322424" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A comparison of the in vivo biochemical responses to exogenous parathyroid hormone-(1-34) [PTH-(1-34)] and PTH-related peptide-(1-34) in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10910428" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The emerging role of parathyroid hormone-related protein as a renal regulating factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8445039" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Parathyroid hormone-related protein (PTHrP) does not regulate 1,25-dihydroxyvitamin D serum levels in hypercalcemia of malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7923831" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Malignancy-associated hypercalcaemia: resolution of controversies over vitamin D metabolism by a pathophysiological approach to the syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8636276" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Differences in bone and vitamin D metabolism between primary hyperparathyroidism and malignancy-associated hypercalcemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16160737" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Continuous PTH and PTHrP infusion causes suppression of bone formation and discordant effects on 1,25(OH)2 vitamin D.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11297578" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Parathyroid hormone-related protein-(1--36) stimulates renal tubular calcium reabsorption in normal human volunteers: implications for the pathogenesis of humoral hypercalcemia of malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18256357" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : PTH-related peptide (PTHrP) in hypercalcemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8099988" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7599053" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Analysis of survival following treatment of tumour-induced hypercalcaemia with intravenous pamidronate (APD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7526033" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Cellular and hormonal mechanisms associated with malignant bone resorption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1955513" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Parathyroid hormone-related protein: elevated levels in both humoral hypercalcemia of malignancy and hypercalcemia complicating metastatic breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7260871" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Tamoxifen-induced hypercalcemia in breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16622738" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Tamoxifen flare hypercalcemia: an additional support for gallium nitrate usage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3855865" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Estrogens and antiestrogens stimulate release of bone resorbing activity by cultured human breast cancer cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21970715" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Flare hypercalcemia after letrozole in a patient with liver metastasis from breast cancer: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21290264" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Anastrozole can cause severe hypercalcaemia mimicking primary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29175022" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Biology and treatment of myeloma related bone disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29175022" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Biology and treatment of myeloma related bone disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29330358" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Pathogenesis of bone disease in multiple myeloma: from bench to bedside.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8364192" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin's disease and non-Hodgkin's lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2316398" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Circulating concentrations of parathyroid hormone-like peptide in malignancy and in hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31841590" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Calcitriol Elevation Is Associated with a Higher Risk of Refractory Hypercalcemia of Malignancy in Solid Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18231957" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : 1,25-dihydroxyvitamin D-mediated hypercalcemia in ovarian dysgerminoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2000889" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Hypercalcemia with excess serum 1,25 dihydroxyvitamin D in lymphomatoid granulomatosis/angiocentric lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19364692" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Hypercalcemia of malignancy with simultaneous elevation in serum parathyroid hormone--related peptide and 1,25-dihydroxyvitamin D in a patient with metastatic renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2541161" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Ectopic production of parathyroid hormone by small cell lung cancer in a patient with hypercalcemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2215618" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Hypercalcemia and ectopic secretion of parathyroid hormone by an ovarian carcinoma with rearrangement of the gene for parathyroid hormone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7684395" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Production of parathyroid hormone by a malignant nonparathyroid tumor in a hypercalcemic patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8855839" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Ectopic production of intact parathyroid hormone by a squamous cell lung carcinoma in vivo and in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16077176" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Parathyroid hormone expression in a patient with metastatic nasopharyngeal rhabdomyosarcoma and hypercalcemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16263810" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Hypercalcemia of malignancy due to ectopic transactivation of the parathyroid hormone gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16188904" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Hypercalcaemia induced by excessive parathyroid hormone secretion in a patient with a neuroendocrine tumour.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21977238" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Ectopic secretion of parathyroid hormone in a neuroendocrine tumor: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23303131" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Humoral hypercalcemia associated with gastric carcinoma secreting parathyroid hormone: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7708588" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Survival in hypercalcaemic patients with cancer and co-existing primary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3336214" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Malignancy and concomitant primary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11395297" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Diagnostic approach to hypercalcemia: relevance of parathyroid hormone and parathyroid hormone-related protein measurements.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34240162" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Rare Causes of Hypercalcemia: 2021 Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17634462" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Vitamin D deficiency.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
